Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis - CC-90001-IPF-001

Updated: 31 March, 2021   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 2


  • Gender(s)

  • 40+

    Age Range

  • 40


  • Recruiting

Treatment Options

Study Arms
Experimental: CC-90001 200 mg PO QD
Drug: CC-90001
Experimental: CC-90001 400 mg PO QD
Drug: CC-90001
Experimental: CC-90001 400 mg PO QD- Sub-Study
Drug: CC-90001
Placebo Comparator: Placebo PO QD
Other: Placebo
Placebo Comparator: Placebo PO QD- Sub-Study
Other: Placebo

Key Eligibility Criteria

Inclusion Criteria: Subject understands and has voluntarily signed and dated an informed consent form 1. Subject is male or female ≥ 40 years of age 2. Diagnosis of IPF is supported by HRCT and historical lung biopsy (surgical lung biopsy [SLB] or cryobiopsy) if available according to guidelines. 3. No features supporting an alternative diagnosis on transbronchial biopsy, bronchoalveolar lavage (BAL), or SLB, if performed. 4. Percent predicted forced vital capacity (% FVC) ≥ 45% and ≤ 95% at Screening 5. Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and ≤ 90% predicted at Screening. 6. Able to walk ≥ 150 meters during the 6-minute walk test (6MWT) at Screening 7. Females of childbearing potential (FCBP) must commit to true abstinence or agree to use two effective birth control methods. 8. Male subjects must practice true abstinence or use a barrier method of contraception. 9. Additional inclusion criteria apply. Progressive Pulmonary Fibrosis (PPF) Sub-Study: 1. Met all inclusion criteria described for IPF subjects other than Inclusion Criterion 5. 2. Features of diffuse fibrosing lung disease of > 10% on HRCT by central reading. 3. Investigator-documented ≥ 5% annualized relative decline in FVC in past 24 months from Screening Visit 1 Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: 1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Subject with a QTcF > 450 msec. 3. Evidence of clinically relevant airways obstruction at Screening. 4. Subjects using therapy targeted to treat IPF. 5. History of latent or active TB, unless there is medical record documentation of successful completion of a standard course of treatment 6. History of hepatitis B and/or hepatitis C, including those considered successfully treated/cured 7. Pregnancy or lactation. 8. Additional exclusion criteria apply.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com